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Abstract
Iota-carrageenan (I-C) is active against respiratory viruses in vitro and was effective as nasal spray in three previous
clinical trials. The current trial served to further investigate I-C in patients with early common cold symptoms.
Methods: This randomized, placebo-controlled, double-blind phase IV trial was conducted in 200 adult patients
with self-diagnosed colds of <48 h’ duration that were confirmed by baseline cold symptom scores. Patients were
to self-administer 0.12 % I-C or placebo spray (NaCl 0.5 %) four times daily for four to ten days and record symptom
information for ten days. Common respiratory viruses were quantified by RT-PCR during pretreatment and on Day 3
or 4. The primary endpoint was the mean total symptom score (TSS) of eight cold symptoms on Days 2–4 (TSS2–4).
Results: Patients in both treatment groups had similar baseline TSSs (mean TSS: 6.75 for I-C and 6.79 for placebo).
Viruses were detected in baseline samples from 53 of 98 I-C patients (54.1 %) and 54 of 97 placebo patients
(55.7 %). Mean ± SE for TSS2–4 was 5.78 ± 0.25 for I-C patients and 6.39 ± 0.25 for placebo (p = 0.0895). Exploratory
analyses after unblinding (TSS2–4 excluding a patient with aberrantly high symptom scores [TSS2–4, ex 1pt]; mean of
TSS over Days 1–4 [TSS1–4]; change in TSS1–4 relative to baseline [TSS1–4, rel]) demonstrated treatment differences in
favor of I-C (p = 0.0364, p = 0.0495 and p = 0.0421, respectively). For patients with quantifiable rhinovirus/enterovirus
at baseline, there was a trend towards greater reduction of virus load at Day 3 or 4 (p = 0.0958; I-C: 90.2 %
reduction in viral load; placebo: 72.0 %). Treatments were well tolerated with no differences in adverse event rates.
Conclusions: The primary endpoint did not demonstrate a statistically significant difference between I-C and
placebo but showed a trend towards I-C benefit. Exploratory analyses indicated significant reduction of cold
symptoms in the I-C group relative to placebo during the first four days when symptoms were most severe, and
also substantiated I-C’s activity against rhinovirus/enterovirus.
Trial registration: NCT01944631 (clinicaltrials.gov)
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Background
The common cold is caused by a variety of respiratory
viruses, such as human rhinoviruses (HRV), corona-
viruses, human enteroviruses (HEV), respiratory syncytial
virus (RSV), parainfluenza viruses, or influenza viruses [1].
Rhinoviruses are the most common cause of respiratory
tract infections in individuals of all ages. In adults, rhinovi-
ruses cause approximately 50 % of common colds and up
to 90 % of colds during the autumn epidemic season.
Common colds are frequent illnesses in both children and
adults; on average, adults report 2.5 episodes per year [2].
It has been estimated that the total economic impact of
non–influenza-related viral upper respiratory tract infec-
tions approaches $40 billion annually [2], and such in-
fections can result in serious and even life-threatening
sequelae in patients with underlying illnesses such as
asthma, COPD or immune compromise. With the excep-
tion of influenza and RSV, there are no vaccinations or
anti-viral medicinal products available for treatment of
infection with the viruses that cause the common cold.
Iota-carrageenan (I-C)—a sulfated polysaccharide found
in some species of red seaweed (Chondrus crispus) — has
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demonstrated antiviral activity against respiratory viruses
in cell culture and in animal models [3, 4]. The I-C poly-
mer seems to bind directly to viruses, preventing viral
attachment to host cells. In vitro and in vivo studies
have demonstrated the effectiveness of I-C against
several viruses such as HRV [4] and influenza A [3].
In vitro tests have established that I-C does not pene-
trate freshly excised bovine nasal mucosa, and there-
fore is not absorbed systemically (data on file, Marinomed
Biotechnology GmbH). Carrageenan is generally recog-
nized as safe (GRAS) for use in food and topical applica-
tions. Because the primary site of infection and replication
of most cold-causing viruses is the nasal mucosa, it was
speculated that early and targeted treatment of the nasal
mucosa with I-C may block viral entry at the level of the
respiratory mucosa, and interfere locally with the propaga-
tion of viral replication.
Therefore, a nasal spray containing 0.5 % saline and
0.12 % iota-carrageenan (I-C nasal spray) has been de-
veloped and registered as a medical device. This product
has recently been licensed to Boehringer Ingelheim, the
sponsor of the current study. Between 2008 and 2011,
three randomized clinical trials (two in adults and one in
children) were conducted comparing I-C nasal spray
with saline solution (placebo). In all 3 trials, there were
indications of efficacy, including significantly reduced
cold symptoms [5]; positive effects on symptoms in pa-
tients in whom less co-medication or no co-medication
was used [6]; significantly reduced viral loads [5–7]; and
faster reduction of common cold symptoms [6, 7].
Treatments were safe and well tolerated [5–7].
The ICICC trial (ICICC: Iota-Carrageenan In Common
Cold) was designed as a controlled evaluation of the safety
and efficacy of I-C in the treatment of patients with early
common cold symptoms. The effects of treatment on cold
symptoms and the duration of the cold and on viral load
were assessed.
Methods
Trial design and patient population
The ICICC trial was conducted at the Common Cold
Center, Cardiff, Wales, UK. It was a randomized, placebo-
controlled, double-blind, two-arm parallel group trial, with
the aim of investigating the efficacy of I-C nasal spray in
comparison with placebo nasal spray for the treatment of
early common cold in adults (≥18 years). The trial was
registered under the clinicaltrials.gov accession number
NCT01944631.
Volunteer patients were recruited by poster advertise-
ments around the Cardiff University campus and by
e-mail to the students and staff of Cardiff University.
Based on the results of a previous trial [5], it was cal-
culated that a sample size of 93 in each group would
have 90 % power to detect the expected difference in
means between the TSS2–4 scores of the groups (see below
for definition of TSS2–4); it was therefore planned to
include a total of 200 patients eligible for randomization.
To be eligible for participation, patients were to have had
common cold symptoms for ≤48 h before trial entry,
based on self-reporting during the screening interviews.
Patients were to rate eight common cold symptoms (head-
ache, muscle ache, chilliness, sore throat, blocked nose,
runny nose, cough, and sneezing) on a 0 to 3 rating scale
[8] (0 = no symptoms, 3 =maximum severity) and were to
have a total symptom score (the sum of these eight
common cold symptoms at baseline) of ≤9. Patients were
also to have a score of ≥1 for at least one of the following
symptoms: sore throat, runny nose, or blocked nose
which reflects the standard cold study design accord-
ing to Jackson.
Inclusion criteria constructed similarly to the previous
3 clinical trials conducted with I-C. Patients with high
symptom scores (≥9) were excluded in order to recruit
only patients in the early stages of a cold and exclude
subjects with later infections. This strategy was designed
to start treatment early to optimize the chance to improve
the clinical course of a cold. This early intervention strat-
egy may have been partially responsible for lowering the
power of the study, since the proportion of patients in the
trial who did not develop full-blown colds was relatively
high (reflected by only about 24 % rhinovirus-positive
patients; see Results and Discussion).
Trial treatment and outcome measures
Patients were instructed to self-administer 1 puff (0.14 mL)
of trial medication to each nostril 4 times per day. Trial
medication was either I-C nasal spray (1.20 g iota-
carrageenan/L in 0.5 % NaCl) or placebo (0.5 % NaCl).
Both patients and investigators were blinded to treatment
allocation. Treatment was to be mandatory for 4 days, and
depending on patient preference, could be continued for
up to 6 additional days, resulting in a maximum treatment
duration of 10 days.
Patients were to record their symptoms once per day
in the evening of Days 1–10 in a symptom diary, using
the 0–3 rating scale for each of the eight cold symptoms
(see above). The primary endpoint of the trial was the
mean total symptom score (TSS) of those documented
eight single cold symptoms calculated as the averaged
daily sum over Days 2–4 (TSS2–4). Secondary endpoints
included the mean of the daily sum of three systemic
common cold symptoms (headache, muscle ache, and
chilliness) over Days 2–4 (SSS2–4); the mean of the daily
sum of 5 single local common cold symptoms (sore throat,
blocked nose, runny nose, cough, and sneezing) over Days
2–4 (LSS2–4); area under the curve (AUC) of daily symp-
tom scores over the 10-day period (AUC-TSS1–10) calcu-
lated as the sum of the eight single cold symptoms over
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Days 1–10; duration of the cold (as determined by patients’
answer in the diary to the question “Do you still have a
cold?” at the end of each treatment day); and the patients’
assessment of efficacy as evaluated at the end of trial visit,
at which patients answered the question “How effective
was the treatment in relieving your common cold symp-
toms?” using a 0–4 scale (0 = poor, 1 = fair, 2 = good, 3 =
very good, or 4 = excellent). Further pre-specified end-
points included TSS at each study day (Days 1–10)
and viral load (change from baseline) on Day 3 or 4
for various virus types. After trial data were unblinded,
three exploratory analyses were performed: assessment
of TSS2–4 excluding a patient with aberrantly high
symptom scores (TSS2–4, ex 1pt); the mean of the TSS
over Days 1–4 (TSS1–4); and change in TSS1–4 relative
to baseline (TSS1–4, rel) to adjust for the potential im-
pact of baseline TSS (TSS0) on TSS1–4 (TSS0 scores
ranged from 3.00–9.00 in the I-C group and from
2.00–9.00 in the placebo group). To calculate TSS1–4, rel,
TSS0 was subtracted from TSS1–4 and the result was
divided by TSS0. In addition, TSS2–4 scores were calcu-
lated for the virus positive subset and the HRV/HEV
positive subset (see Analysis sets below for definition).
Safety was assessed on the basis of incidence of treatment-
emergent adverse events (AEs) and overall tolerability was
assessed by the patients themselves and recorded by the
investigator at the final visit.
Viral assessment
Respiratory viruses and viral load were determined from
nasopharyngeal lavage samples obtained at baseline and on
either Day 3 or 4 [9]. Viral presence was to be determined
for all patients using both qualitative and quantitative tests
for respiratory viruses. Real-time polymerase chain reaction
(RT-PCR) was used for qualitative determinations of the
presence of influenza A and B, picornaviruses, HRV/HEV,
human bocavirus, human metapneumovirus, coronaviruses
229E, HKU1, NL63, and OC43, adenovirus, human pare-
chovirus, respiratory syncytial virus, and parainfluenza virus
types 1–4. Quantitative viral loads for HRV and HEV were
determined using the panenterhino/Ge/08 assay [10, 11].
Quantitative viral loads for influenza A and B and corona-
viruses 229E, HKU1, NL63, and OC43 were assessed
according to Garbino et al. [12, 13]. The panenterhino/Ge/
08 assay provided quantifiable HRV and HEV viral load
results; however, in some patients, virus was detectable but
viral loads were below the level of quantification of the test.
Such patients were considered to be virus-positive, but
non-quantifiable (that is, a qualitative positive result). The
total number of virus-positive patients was obtained by
summing up the number of patients who had a positive
result on any qualitative assay, or who had a detectable
quantitative (quantifiable or non-quantifiable) result on the
panenterhino/Ge/08 assay.
Analysis sets
Two main analysis sets (the treated set and the full ana-
lysis set [FAS]) were evaluated. The treated set included
all patients who were documented to have taken at least
one dose of trial medication, and was used for safety
analyses. The FAS included patients documented to have
taken at least one dose of trial medication, for whom a
baseline TSS was recorded, and who supplied data for
assessment of the primary endpoint. The FAS was used
for analysis of the primary and secondary endpoints.
Three analysis subsets within the FAS were also defined
after unblinding, and included 1) the virus positive sub-
set (those patients whose nasal lavage specimens yielded
a least one positive qualitative or a detectable quantita-
tive [quantifiable or non-quantifiable] result at baseline);
2) the HRV/HEV positive subset (those patients whose
lavage yielded a least a detectable [quantifiable or non-
quantifiable] result on the panenterhino/Ge/08 assay at
baseline); and 3) the quantifiable HRV/HEV subset (those
patients who had a quantifiable result on the panenter-
hino/Ge/08 assay at baseline). These subsets were used for
analysis of additional exploratory endpoints.
Statistical methods
The primary endpoint TSS2–4 was analyzed using an ana-
lysis of covariance (ANCOVA) adjusting for continuous
covariates ‘TSS0’ and ‘treatment’. Differences between I-C
and placebo treatment groups were assessed based on the
adjusted means and the corresponding two-sided 95 % con-
fidence intervals (CIs). The secondary endpoints SSS2-4,
LSS2–4, and AUC-TSS1–10 (adjusted for TSS0 and treat-
ment) were analyzed similarly. The three exploratory end-
points TSS2–4, ex 1pt, TSS1–4, and TSS1–4, rel were analyzed
in the same way as the primary endpoint, that is, by
adjusting for ‘TSS0’ and ‘treatment’. For all the above
endpoints, missing single symptom scores at baseline
and at any post-baseline measurement time were re-
placed by zero, if at least one of the eight symptom
scores was available. Thereafter, missing daily TSS, LSS
and SSS data were replaced the last observation carried
forward procedure.
The duration of the cold was examined by recording the
time to loss of cold, defined by the first “no” response to
the question “Do you still have a cold?” in the patient’s
daily symptom diary. The log rank test stratifying for TSS0
was used to compare treatment groups. The endpoint
variable was censored at day 10 if a patient did not recover
from his or her cold. To test whether patients’ assessment
of efficacy differed between the I-C group and the placebo
group, an ordinal logistic regression model adjusting for
TSS0 was applied to the efficacy score (0–4) provided by
patients. Missing entries were assigned the least favorable
category.
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The analysis of the endpoint variable TSS at each
study day (Days 1–10) used a restricted maximum
likelihood-based repeated measures approach, using all
longitudinal TSS data from Days 1–10. The statistical
model included the fixed categorical effects of treatment,
day and treatment-by-day interaction and the continu-
ous covariate of TSS0. An unstructured covariance struc-
ture was used to model within-patient errors. Missing
single symptom scores at baseline and at any post-
baseline measurement time were replaced by 0, if at least
one of the 8 symptom scores was available. If a patient
had a missing TSS at a specific day and all subsequent
days until Day 10 and the cold ended on that day (that
is, the question “Do you still have a cold” was answered
by “no” at that day at latest), the missing TSS values for
that and the subsequent days until Day 10 were replaced
by 0. For all other cases no imputation of missing TSS
values was performed.
The mean change in viral load from baseline was
adjusted for the continuous covariates ‘baseline viral load’
and ‘treatment’ using an ANCOVA. Differences between
I-C and placebo treatment were assessed based on the
adjusted means and the corresponding 95 % CIs, which
were calculated using a two-sided approach. For quantita-
tive viral load analyses, missing values and values below
the limit of quantification (LOQ) were replaced with the
LOQ value.
Results
Approximately 800 patients were evaluated with respect
to symptomatology and duration of symptoms (pres-
creening); of these, 201 were formally enrolled and
screened. Of the enrolled patients, one was not random-
ized, and 200 were randomized and treated (I-C, N =
100; placebo, N = 100). Overall, 97.0 % of the 200 en-
tered patients completed trial treatment, and 3.0 %
prematurely discontinued treatment with trial medica-
tion. The proportion of patients discontinuing treat-
ment was similar for the treatment groups (I-C: 2 of
100 patients, 2.0 %; placebo: 4 of 100 patients, 4.0 %).
The most frequent reason for trial discontinuation
was being lost to follow-up (I-C: 1 patient; placebo: 3
patients). Of the 200 treated patients, 98 in the I-C
group and 97 in the placebo group provided data for
the primary endpoint and were included in the FAS
(Fig. 1).
Including the 200 patients who were treated, baseline
demographic characteristics were comparable between
the I-C and placebo groups (Table 1).
Primary endpoint
The primary endpoint of TSS2–4 was lower for the I-C
group (5.78, 95 % CI: 5.28–6.28) than for the placebo
group (6.39, 95 % CI: 5.89–6.89), but the difference was
not statistically significant (−0.61, 95 % CI: −1.32–0.10;
p-value 0.0895; Table 2).
Secondary and other endpoints
For the secondary endpoints SSS2–4, LSS2–4, and AUC-
TSS1–10, there were no statistically significant differences
between I-C and placebo (Table 3).
Mean duration of time to ‘no cold’ was equivalent
between the groups, at 7.5 days for I-C and 7.4 days for
placebo. The patients’ overall assessment of efficacy was
similar for I-C and placebo (OR = 1.11, 95 % CI: 0.67–
1.84, p = 0.6954). For both I-C and placebo, the most
frequent patient assessment was ‘good’ (I-C: 33.7 %; pla-
cebo: 36.1 %) and the second most frequent assessment
was ‘fair’ (I-C: 28.6 %; placebo: 33.0 %).
For TSS at each study day (Days 1–10), the mean daily
TSS values were highest for both groups during the four
mandatory treatment days. The TSS peaked at Day 2 in
the placebo group whereas the TSS in the I-C group
decreased steadily without reaching a maximum on Day
2 (Fig. 2). TSS values were lower for the I-C group than
for the placebo group on Days 1–4 (mandatory treat-
ment days); the largest differences were observed on
Days 1 and 2 of treatment. After Day 4, the TSS values
were lower for the placebo group than for the I-C group.
Exploratory analyses of efficacy
After unblinding, three previously unplanned analyses
were performed to provide a better understanding of the
primary endpoint. The data for a patient with a TSS2-4
of 16.7 (treated in the I-C group) was removed for an
exploratory analysis, because his on-treatment symptom
scores were well out of range when compared with the
adjusted mean values of 6.39 for placebo and 5.77 for I-
C patients (Table 2), suggesting that the patient may
have misunderstood the process of symptom reporting.
This aberrantly high symptom score was evident over
the entire treatment period of 10 days. Furthermore, no
respiratory viruses were detectable in his nasopharyngeal
samples. Excluding the data for this patient resulted in
an adjusted mean TSS2–4 that was statistically signifi-
cantly lower for the I-C group (TSS2–4, ex 1 pt) compared
with the placebo group (p = 0.0364; Table 4).
Because I-C binds to viruses and prevents their entry
into cells [4, 5], an immediate effect on symptom scores
could also reasonably be expected; in addition, the TSS
for the placebo group was increasing from pre-treatment
(baseline) to Day 2, indicating progression of the cold.
Therefore, a sensitivity analysis was performed using the
mean daily TSS over the mandatory treatment Days
1–4 (TSS1-4). For the adjusted mean TSS1-4, there
was a statistically significant difference in favour of
I-C (p = 0.0495; Table 4).
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Finally, in order to adjust for the baseline severity of
the cold, the TSS1–4 was analysed relative to baseline
(TSS1-4, rel), yielding a statistically significant difference
in favour of I-C (p = 0.0421; Table 4).
An exploratory analysis in the subset of 107 patients
who tested positive for any virus at baseline yielded a
trend in favor of I-C; average adjusted TSS2–4 scores
were 0.80 points lower for the I-C group compared with
placebo (p = 0.0986; Table 4). In the subset of 55 patients
who were positive for rhinovirus/enterovirus at baseline,
average adjusted TSS2–4 values were 0.36 points lower
than placebo (p = 0.5820; Table 4).
Virologic analyses
Including data from both qualitative and quantitative
assays, the proportion of patients testing positive for
virus at baseline was 54.1 % (53 of 98 patients) in the
I-C group and 55.7 % (54 of 97 patients) in the placebo
group (Table 5). In qualitative assays, the most frequent
viruses identified were picornaviruses (I-C: 26.5 % of
Fig. 1 Disposition of trial patients. 1Placebo (PBO), 2Full analysis set, 3One patient with extreme outlier TSS baseline scores was excluded
from some exploratory analyses, 4Virus positive patients were those with a positive qualitative test at baseline and/or a detectable
quantitative (quantifiable or non-quantifiable) result on a quantitative test at baseline, 5Defined as a detectable quantitative (quantifiable
or non-quantifiable) result on panentorhino/Ge/08 assay, 6Quantifiable result on panenterhino/Ge/08 assay
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patients, placebo: 26.8 %) and coronaviruses (I-C: 22.4 %,
placebo: 19.6 %; Table 5). Between baseline and Day 3 or
4, 7 of the 53 virus-positive patients in the I-C group con-
verted to virus-negative (13.2 %), as did 8 of 54 patients in
the placebo group (14.8 %). Conversely, 4 of the 44
patients in the I-C group (9.1 %) and 5 of the 43 patients
in the placebo group (11.6 %) who were virus-negative at
baseline converted to virus-positive by Day 3 or 4.
As a post-hoc analysis, the quantitative data for viral
types identified in at least 2 patients in each treatment
group at baseline were analysed (coronavirus NL63,
coronavirus OC43, and quantified panenterhino/Ge/08
assay). For the viruses quantified with the panenterhino/
Ge/08 assay, there was a more substantial reduction in
virus load in the I-C group (90.2 % compared with
72.0 % for placebo), although this did not reach statistical
significance (Table 6). For the coronaviruses, decreases in
mean virus quantity from baseline to Visit 2 was similar
between the placebo and I-C groups (reduction of 94 % or
greater).
Safety and tolerability
During this trial, there were no serious AEs or deaths.
Twelve patients (6.0 %) reported an AE; the frequency
was similar between treatment groups, at 5 of 100 pa-
tients (5.0 %) in the I-C group and 7 of 100 patients
(7.0 %) in the placebo group. AEs of severe intensity
were reported for 3 of 100 patients (3.0 %) in the I-C
group (one patient with both headache and migraine,
one patient with toothache, and one patient with mal-
aise) and for 5 of 100 patients (5.0 %) in the placebo
group (one patient each with headache, migraine, nau-
sea, sore throat, and fatigue). One patient in the placebo
group discontinued treatment due to an AE (moderate
epistaxis). The patients’ assessment of tolerability was
similar between treatment groups, with the majority rat-
ing the tolerability of the nasal spray as excellent, very
good, or good (I-C: 87 patients, 88.8 %; placebo: 91
patients, 93.8 %). Only 1 patient in the I-C group (1.0 %)
and 2 patients in the placebo group (2.0 %) assessed the
tolerability of treatment as poor. Both treatments were
therefore considered to be safe and well-tolerated.
Table 1 Demographic characteristics – treated set
I-C Placebo Total
Number of patients, N (%) 100 (100.0) 100 (100.0) 200 (100.0)
Sex, N (%)
Male 40 (40.0) 38 (38.0) 78 (39.0)
Female 60 (60.0) 62 (62.0) 122 (61.0)
Race, N (%)
Asian 8 (8.0) 2 (2.0) 10 (5.0)
Black or African American 2 (2.0) 1 (1.0) 3 (1.5)
Hawaiian or Pacific Islander 0 1 (1.0) 1 (0.5)
White 90 (90.0) 96 (96.0) 186 (93.0)
Age, mean (SD) [years] 20.01 (2.37) 19.93 (1.90) 19.97 (2.14)
BMI, mean (SD) [kg/m2] 23.98 (3.67) 23.66 (3.89) 23.82 (3.78)
Smoking history, N (%)
Never smoked 80 (80.0) 83 (83.0) 163 (81.5)
Ex-smoker 7 (7.0) 4 (4.0) 11 (5.5)
Current smoker 13 (13.0) 13 (13.0) 26 (13.0)
Alcohol history, N (%)
Does not drink 5 (5.0) 4 (4.0) 9 (4.5)
No significant drinking 95 (95.0) 96 (96.0) 191 (95.5)
BMI body mass index, SD standard deviation
Table 2 Total symptom scores over Days 2 to 4 (TSS2-4),
ANCOVA-adjusted means, FAS
I-C vs. placebo
N Adjusteda
mean (SE)
Adjusteda mean
(SE) differenceb
95 % CI p-value*
TSS0
c
I-C 98 6.75 (0.17)
Placebo 97 6.79 (0.18)
TSS2-4
I-C 98 5.78 (0.25) −0.61 (0.36) (-1.32, 0.10) 0.0895
Placebo 97 6.39 (0.25)
CI confidence interval, SE standard error
*For ANCOVA-adjusted comparison of placebo with I-C
aThe means were adjusted for TSS0
bA negative treatment difference favored I-C
cTSS0 values are unadjusted means
Table 3 Secondary symptom score endpoints SSS2-4, LSS2-4, and
AUC-TSS1-10, ANCOVA-adjusted means, FAS
I-C vs. placebo
N Adjusteda
mean (SE)
Adjusteda mean
(SE) differenceb
95 % CI p-value*
SSS2–4
I-C 98 1.12 (0.10) −0.18 (0.15) (-0.46, 0.11) 0.2310
Placebo 97 1.30 (0.10)
LSS2–4
I-C 98 4.66 (0.22) −0.44 (0.30) (-1.04, 0.16) 0.1465
Placebo 97 5.10 (0.22)
AUC-TSS1–10
I-C 98 41.94 (2.19) 0.73 (3.10) (-5.39, 6.85) 0.8148
Placebo 97 41.21 (2.20)
CI confidence interval, SE standard error
*For ANCOVA-adjusted comparison of placebo with I-C
aThe means were adjusted for baseline SSS, LSS, or TSS
bA negative treatment difference favored I-C
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Discussion
This randomized, double-blind, and placebo-controlled
ICICC trial was conducted to further evaluate the safety
and efficacy of I-C in the treatment of patients with early
common cold symptoms, and was conducted at one study
site, primarily among university students who were in
apparent good health except for early common cold
symptoms. The analyses from the ICICC trial support the
findings of three previous randomized clinical trials, which
examined I-C nasal spray in adults [5, 7] and children [6]
with acute common cold symptoms: in 35 adult patients,
administration of I-C nasal spray significantly reduced
cold symptoms and the viral concentration in nasal
lavages [5]; in 203 adult patients, cold duration was signifi-
cantly shorter in virus-positive patients treated with I-C,
viral load was significantly reduced, and there was a sig-
nificantly faster reduction of common cold symptoms
after the first 3 days of treatment [7]; and in 153 children,
although there was no significant difference between the
I-C group and the placebo group for mean total symptom
score, exploratory analyses indicated a positive effect on
symptoms in patients in whom less co-medication or no
co-medication was used [6]. In the ICICC trial, although
the primary endpoint TSS2–4 did not demonstrate a statis-
tically significant difference between I-C and placebo,
there was a clear trend towards benefit of I-C treatment.
Consistent trends in favor of I-C for secondary end-
points and statistically significant outcomes for explora-
tory analyses were also observed for the ICICC trial. The
finding that nominally greater treatment effects were
seen in the ICICC trial among patients who were virus-
positive, is supported by a pooled analysis by Koenigho-
fer [14], which combined the Fazekas and Ludwig trials
[6, 7]. The pooled analysis examined only those patients
who were virus-positive, and showed that nominal re-
sponse rates were higher in virus-positive patients than
in all participants of the Ludwig and Fazekas trials.
There may be several reasons for the unexpectedly low
power of the trial, which resulted in trends rather than
statistically significant outcomes for the primary endpoint
and HRV/HEV viral load reductions. First, the proportion
of patients for whom a respiratory virus could be detected
Fig. 2 Adjusted mean TSS values with standard error for each day of the trial (data at baseline are displayed as unadjusted mean values)
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was smaller than anticipated; respiratory viruses (all
groups/types analysed) were found at baseline in only
54.9 % of patients (54.1 % in the I-C group and 55.7 % in
the placebo group). Efforts were made to recruit patients
with the earliest onset of a common cold. Thus, self-
reported cold symptoms were used for patient inclusion
criteria, without the requirement for demonstration of
virus positivity to enter treatment. Since the early symp-
toms of common colds may be rather non-specific for
respiratory virus infection, these symptoms may present
in other conditions such as vasomotor rhinitis, in which
certain nonspecific stimuli including changes in environ-
ment (temperature, humidity, or barometric pressure),
airborne irritants (odors or fumes), dietary factors (spicy
food or alcohol) or emotional factors trigger nasal symp-
toms. Patients inadvertently included with non-infectious
conditions would not be expected to respond clinically to
antiviral therapy, and therefore are likely to cause an
under-estimation of any true antiviral treatment effect.
Consistent with this, the ICICC trial demonstrated that
among those patients who had quantifiable virus at base-
line, the I-C patients had a greater decrease in viral load
than did placebo patients, suggesting an antiviral effect of
I-C. In addition, TSS2–4 scores in the patients who were
virus-positive at baseline showed strong trend in favor of
I-C. However, since this was a subset of the total en-
rolled population, the virus-positive subset was under-
powered for the TSS2–4 score endpoint. In particular,
the percentage of patients with HRV/HEV identified at
baseline was substantially smaller than anticipated: only
23.6 % had quantifiable virus (22.4 % in the I-C group and
24.7 % in the placebo group). Other studies using both
molecular methods and viral culture have demonstrated
that human rhinoviruses are the etiologic agent in
50–90 % of common colds [1, 15]. The current trial
was also conducted primarily in the fall (October
until February), which includes the period of greatest
HRV infection incidence [1, 15]. Because virus shedding
tends to be the greatest in the first several days of infec-
tion and generally continues for up to 2 weeks, it is
unlikely that the low positive rate for HRV/HEV infection
was due to missing the window of HRV shedding. More
likely, the current study was conducted during a season of
low HRV prevalence, resulting in fewer than expected
infections among trial patients. In two previous clinical
trials conducted with I-C [6, 7], the number of patients
with confirmed HRV infection was higher than in the
current trial, at 46 % [6] and 30 % [7] (although these
values are as well lower than the percentages reported for
other studies [1, 15]). Therefore, the smaller-than-
expected number of patients infected with the HRV/HEV
viruses likely limited the ICICC trial’s ability to differenti-
ate between the I-C and placebo treatments.
A second issue that affected the analysis of the trial was
the inclusion of one patient treated in the I-C group
whose TSS scores were much higher than expected and
Table 4 Exploratory analyses of total symptom scores, ANCOVA-adjusted means
I-C vs. placebo
N Adjusteda mean (SE) Adjusteda mean (SE) differenceb 95 % CI p-value*
TSS2–4, ex 1 pt
I-C 97 5.67 (0.24) −0.72 (0.34) (−1.40, −0.05) 0.0364
Placebo 97 6.39 (0.24)
TSS1-4
I-C 98 6.02 (0.21) −0.60 (0.30) (−1.19, −0.00) 0.0495
Placebo 97 6.62 (0.21)
TSS1–4, rel
I-C 98 −0.08 (0.05) −0.13 (0.06) (−0.25, −0.01) 0.0421
Placebo 97 0.05 (0.05)
Subset analyses
TSS2–4, virus positive patients
I-C 53 5.87 (0.34) −0.80 (0.48) (−1.75, 0.15) 0.0986
Placebo 54 6.67 (0.34)
TSS2–4, HRV/HEV positive patients
I-C 27 6.08 (0.46) −0.36 (0.65) (−1.66, 0.94) 0.5820
Placebo 28 6.44 (0.46)
CI confidence interval
*For ANCOVA-adjusted comparison of placebo with I-C
aThe means were adjusted for baseline TSS
bA negative treatment difference favours I-C
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were much different than those of other trial participants.
This patient reported exceptionally high symptom scores
over the entire treatment period of 10 days; his AUC-
TSS1–10 was more than 3-fold higher than the overall
population mean value. Interestingly, no virus was de-
tected from this patient either at baseline or in a follow-up
sample. While there is no ready explanation for these
aberrant values, it is possible that this patient misinter-
preted the symptom scoring methodology. When the
primary endpoint TSS2–4 was re-evaluated excluding the
data from this patient, the difference between the I-C and
placebo patients became statistically significant.
Two other exploratory analyses further support the
conclusion that I-C was efficacious. Because I-C may
have had an early effect on symptoms, the assessment of
on-treatment symptom scores was broadened to include
Day 1. The comparison of TSS1-4 between I-C and pla-
cebo groups demonstrated a statistically significant effect
of I-C, and a statistically significant change in TSS1–4
relative to baseline. Two additional exploratory analyses,
although performed on very small samples, did not
reach statistical significance, but also support the asser-
tion of I-C efficacy: TSS2–4 scores in PCR-confirmed
respiratory virus-positive patients were on average 0.8
points lower in the I-C group compared with placebo,
and TSS2–4 scores in patients with PCR-confirmed rhino-
virus infection were also on average 0.4 points lower in
the I-C group.
The day-by-day TSS scores indicated an advantage for
I-C on Days 1 and 2, which appeared to be lost by Days
4–5. It is not clear why the apparent TSS advantage
disappeared on the later treatment days; however, the
placebo was a saline nasal spray, which may have had
Table 6 Change in panenterhino/Ge/08 assay viral load in nasal secretions - patients with quantifiable baseline viral load, ANCOVA-
adjusted means
I-C vs. placebo
N Adjusteda mean (SE) Adjusteda mean (SE) differenceb 95 % CI p-value*
Baseline [log (copies/mL)]c
I-C 22 5.840 (0.200)
Placebo 24 6.139 (0.201)
Change from baseline, [log (copies/mL)]
I-C 22 −1.007 (0.191) −0.453 (0.266) −0.990, 0.084 0.0958
Placebo 24 −0.554 (0.183)
Reduction from baseline (%)c,d
I-C 22 90.2
Placebo 24 72.0
CI confidence interval, SE standard error
*For ANCOVA-adjusted comparison of placebo with I-C
aThe means were adjusted for baseline viral load
bA negative treatment difference favored I-C
cBaseline values are unadjusted means
dCalculated according to Eccles et al. [5]
Table 5 Viruses identified at baseline in trial participants
I-C Placebo
Total number of patients tested (N) 98 97
Number of virus positive patientsa, b (N, %) 53 (54.1) 54 (55.7)
Influenza Type A 1 (1.0) 2 (2.1)
Picornavirus (including HRV and HEV) 30 (30.6) 28 (29.3)
Positive qualitative picornavirus assay 26 (26.5) 26 (26.8)
Positive qualitative enterovirus assay 2 (2.0) 0 (0.0)
Positive resultc on panenterhino/Ge/08 assay 27 (27.6) 28 (28.9)
Quantifiable result on panenterhino/Ge/08 assay 22 (22.4) 24 (24.7)
Human metapneumovirus 0 (0.0) 1 (1.0)
Coronavirus 23 (22.4) 19 (19.6)
Coronavirus 229E 1 (1.0) 2 (2.0)
Coronavirus HKU1 1 (1.0) 2 (2.1)
Coronavirus NL63 9 (9.2) 4 (4.1)
Coronavirus OC43 12 (12.2) 11 (11.3)
Adenovirus 0 (0.0) 2 (2.1)
Respiratory syncytial virus 0 (0.0) 1 (1.0)
Parainfluenza 5 (5.1) 5 (5.2)
Type 1 3 (3.1) 0 (0.0)
Type 2 1 (1.0) 1 (1.0)
Type 4 1 (1.0) 4 (4.1)
Categories are not exclusive; patients may appear in more than one category
aEight patients were positive for 2 different viruses
bNo patient tested positive for influenza B, human bocavirus, human paraecho
virus, or parainfluenza 3
cDetectable (quantifiable or non-quantifiable) result at baseline
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some clinical benefit from saline irrigation of the nasal
passages [16–18].
The I-C spray is registered and marketed as medical
device in several European countries and is intended to
be used in patients with early cold symptoms. Data from
several experiments suggest that the mechanism of
action may be prevention of binding to attachment sites
and/or interference of viral entry. First, in vitro studies
have demonstrated activity against a variety of viruses
– various strains of HRV and influenza and herpes-
virus, denguevirus, and papillomavirus [3, 4, 19–21].
This non-specificity suggests the absence of a specific
direct-acting antiviral (DAA). Secondly, the observed
antiviral effects occurred early in the infection cycle,
most likely during the stages of attachment and/or
entry, and the antiviral effect tended not to be I-C
concentration-dependent. It is, therefore, unlikely that
carrageenan’s effect is that of a DAA targeted to the
metabolic or reproductive mechanisms. Since a variety
of viruses cause the common cold and since the virus
infection cycles typically involve binding and entry
with nasal mucosal cells, the antiviral properties of
iota carrageenan represents an attractive and promis-
ing option for treatment.
Published clinical evidence concerning the frequencies
of detectable viruses varies but with modern techniques,
viruses (particularly rhinoviruses) have been found in up
to 90 % of patients suffering from cold symptoms. It can
therefore be expected that in real-life conditions pa-
tients/consumers who empirically choose to use the I-C
spray have a relatively high likelihood of being infected
with rhinovirus or one of a variety of respiratory viruses
that manifest with the common cold symptoms. The
uncertainty of true infection in such a setting is counter-
balanced by the very low intolerance and toxicity rates
of the I-C spray and its relative inexpensiveness, thus
giving favorable potential benefit-risk and benefit-cost
ratios to the empiric use of the I-C spray.
In clinical trials of cough & cold, a substantial propor-
tion of studies demonstrate trends but may not reach
statistically significant efficacy outcomes. This observa-
tion may be due to the large variability in the disease
severity between native infection and patients recruited
in the early stages of a cold. When a controlled clinical
trial tries to recruit patients at the earliest stages of a
common cold - when symptoms are still emerging and
are mild - patients may incorrectly believe they are com-
ing down with a cold, prior to full blown cold symptoms.
The relatively low frequency of rhinovirus-positive pa-
tients in the ICICC study demonstrates that there is
often a trade-off when this standard design is used for
cold studies. The peculiarities of the outcome of the
ICICC study are also useful in that they may trigger a dis-
cussion among the scientific community about more
suitable study designs to investigate common cold
treatments.
Furthermore, the results of the ICICC study are in line
with many other common cold studies which showed rela-
tively small effects of treatment on symptom severity or
duration. One example is the study by Barrett et al. on
Echinacea which showed as well trends in the direction of
benefit, amounting to an average half day reduction in the
duration of a week-long cold, or an approximate 10 % re-
duction in overall severity. The authors concluded that
“while these results do not allow us to reject the null
hypothesis and confidently claim evidence-of-benefit, data
are also insufficient to exclude the possibility of a clinically
significant effect” [22].
Although not addressed in the ICICC trial, I-C’s anti-
viral properties lead to speculation that its use might de-
crease cold transmission to patients’ family members
and other social contacts.
Conclusions
Although the ICICC study failed to reach statistically sig-
nificant outcomes for the primary and secondary end-
points, strong trends favouring treatment effect of I-C
were observed. The primary and secondary endpoints
consistently tended to be improved in the I-C spray group
compared to the placebo group, with clinically relevant
effect sizes, even though the population included patients
with low baseline scores. Several rational and important
exploratory analyses led to statistically significant and
clinically relevant outcome differences. Unfortunately, the
relatively low numbers of subjects with demonstrated viral
infection limited study conclusions. Nonetheless, the out-
come of the ICICC study is supported by previous
evidence of I-C’s in vitro antiviral activity and symptom
and viral reduction in prior cold studies. The ICICC trial’s
outcome supports I-C spray as representing a potentially
useful treatment option for the common cold. Trial results
show it to be safe, well-tolerated, and minimally invasive,
as well as suggesting efficacy.
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